How much funding has Dioseve raised?

Dioseve has raised $16.7M in total funding, most recently a Venture Round.

Who are Dioseve's investors?

Dioseve's investors include Archetype, DG Daiwa Ventures, D4V, Shionogi, Pangaea Ventures.

Where is Dioseve headquartered?

Dioseve is headquartered in Tokyo, Japan.

What industry is Dioseve in?

Dioseve operates in Biotech, Healthcare.

Dioseve

Providing novel possibilities for all lives.

Tokyo, Japan · Founded 2021 · $16.7M raised

Biotech

Healthcare

Headquarters: Tokyo
Employees: 1–10
Founded: 2021
Business Model: B2B

Website: dioseve.com
Total Funding: $16.7M
Last Round: $9.7M Venture RoundJun 2026
Rounds: 2

About

Dioseve is a Tokyo-based fertility biotech developing iPS cell-derived ovarian support technologies to improve IVF treatment outcomes. The company uses proprietary differentiation technology to induce oocytes and ovarian somatic cells from iPS cells at high efficiency, targeting age-related fertility decline. Dioseve secured JPY 1.45 billion in June 2026 and counts SHIONOGI CVC among its investors.

Summary

Dioseve is a Biotech company based in Tokyo, Japan, founded in 2021. It has raised $16.7M in total across 2 rounds, most recently a $9.7M Venture Round round in Jun 2026. Investors include Archetype, DG Daiwa Ventures and D4V.